12:00 AM
 | 
Aug 15, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/12 cls
Charles River Laboratories International Inc. (NYSE:CRL) Jefferies David Windley Price target Hold -6% $30.84
Windley lowered his target to $33 from $40 after the tool supplier reported 2Q11 net sales from continuing operations of $288.3M, essentially flat vs. 2Q10. Windley believes the company's preclinical services (PCS) segment is stable but continues to hamper top-line growth. 2Q11 net sales for the PCS segment came in at $110.1M, down 9% from 2Q10 due to continued soft demand from large pharmas. Windley is cautious about the company's expectation that PCS sales will improve as pharma moves forward with facility closures and more extensive outsourcing.
GTx Inc. (NASDAQ:GTXI) Cowen Eric Schmidt Upgrade Neutral (from underperform) -11% $2.97
Schmidt noted...

Read the full 868 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >